- Rheumatoid Arthritis Slideshow Pictures
- Take the RA Quiz
- Joint-Friendly Exercises to Reduce RA Pain Slideshow
Does Kineret (anakinra) cause side effects?
Kineret (anakinra) is an injectable, interleukin-1 (IL-1) receptor antagonist that blocks the effects of human interleukin-1 used to treat the signs and symptoms of moderate to severe rheumatoid arthritis in individuals 18 years of age or older.
It is used in patients who have failed at least one other disease-modifying drug (DMARD) used to treat rheumatoid arthritis. Kineret may be used alone or in combination with other drugs. Kineret is also used to treat neonatal-onset multisystem inflammatory disease (NOMID) due to cryopyrin-associated periodic syndromes (CAPS).
Common side effects of Kineret include:
- injection site reactions (redness, swelling and pain),
- flu-like symptoms,
- diarrhea, and
Serious side effects of Kineret include:
- increase in infections and
- a decrease in the number of white blood cells (neutropenia) and platelets.
What are the important side effects of Kineret (anakinra)?
The most common side effects are reactions at the site of injection, for example, redness, swelling and pain.
Other minor side effects include:
The most serious side effects are an increase in infections and a decrease in the number of white blood cells (neutropenia) and platelets.
Anakinra should not be started in individuals with active infections.
Infections occur more frequently when anakinra is used in combination with drugs that block tumor necrosis factor.
Kineret (anakinra) side effects list for healthcare professionals
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Clinical Studies Experience In RA
The most serious adverse reactions were:
- Serious Infections
- Neutropenia, particularly when used in combination with TNF blocking agents
The most common adverse reaction with Kineret is injection-site reactions.These reactions were the most common reason for withdrawing from studies.
The data described herein reflect exposure to Kineret in 3025 patients, including 2124 exposed for at least 6 months and 884 exposed for at least one year. Studies 1 and 4 used the recommended dose of 100 mg per day. The patients studied were representative of the general population of patients with rheumatoid arthritis.
The most common and consistently reported treatment-related adverse event associated with Kineret is injection-site reaction (ISR). In Studies 1 and 4, 71% of patients developed an ISR, which was typically reported within the first 4 weeks of therapy. The majority of ISRs were reported as mild (72.6% mild, 24.1% moderate and 3.2% severe). The ISRs typically lasted for 14 to 28 days and were characterized by 1 or more of the following:
- inflammation, and
In Studies 1 and 4 combined, the incidence of infection was 39% in the Kineret-treated patients and 37% in placebo-treated patients during the first 6 months of blinded treatment. The incidence of serious infections in Studies 1 and 4 was 2% in Kineret-treated patients and 1% in patients receiving placebo over 6 months.
The incidence of serious infection over 1 year was 3% in Kineret-treated patients and 2% in patients receiving placebo. These infections consisted primarily of bacterial events such as cellulitis, pneumonia, and bone and joint infections.
Majority of patients (73%) continued on study drug after the infection resolved. No serious opportunistic infections were reported. Patients with asthma appeared to be at higher risk of developing serious infections when treated with Kineret (8 of 177 patients, 4.5%) compared to placebo (0 of 50 patients, 0%).
In open-label extension studies, the overall rate of serious infections was stable over time and comparable to that observed in controlled trials. In clinical studies and postmarketing experience, cases of opportunistic infections have been observed and included fungal, mycobacterial and bacterial pathogens. Infections have been noted in all organ systems and have been reported in patients receiving Kineret alone or in combination with immunosuppressive agents.
In patients who received both Kineret and etanercept for up to 24 weeks, the incidence of serious infections was 7%. The most common infections consisted of bacterial pneumonia (4 cases) and cellulitis (4 cases). One patient with pulmonary fibrosis and pneumonia died due to respiratory failure.
Among 5300 RA patients treated with Kineret in clinical trials for a mean of 15 months (approximately 6400 patient years of treatment), 8 lymphomas were observed for a rate of 0.12 cases/100 patient years. This is 3.6 fold higher than the rate of lymphomas expected in the general population, based on the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) database.3
An increased rate of lymphoma, up to several fold, has been reported in the RA population, and may be further increased in patients with more severe disease activity. Thirty-seven malignancies other than lymphoma were observed. Of these, the most common were breast, respiratory system, and digestive system.
There were 3 melanomas observed in Study 4 and its long-term open-label extension, greater than the 1 expected case. The significance of this finding is not known. While patients with RA, particularly those with highly active disease, may be at a higher risk (up to several fold) for the development of lymphoma, the role of IL-1 blockers in the development of malignancy is not known.
In placebo-controlled studies with Kineret, 8% of patients receiving Kineret had decreases in total white blood counts of at least one WHO toxicity grade, compared with 2% of placebo patients. Nine Kineret-treated patients (0.4%) developed neutropenia (ANC < 1 x 109/L). 9 % of patients receiving Kineret had increases in eosinophil differential percentage of at least one WHO toxicity grade, compared with 3 % of placebo patients.
Of patients treated concurrently with Kineret and etanercept 2% developed neutropenia (ANC < 1 x 109/L). While neutropenic, one patient developed cellulitis which recovered with antibiotic therapy. 2% of patients receiving Kineret had decreases in platelets, all of WHO toxicity grade one, compared to 0% of placebo patients.
As with all therapeutic proteins, there is potential for immunogenicity. In Studies 1 and 4, from which data is available for up to 36 months, 49% of patients tested positive for anti-anakinra binding antibodies at one or more time points using a biosensor assay.
Of the 1615 patients with available data at Week 12 or later, 30 (2%) tested positive for neutralizing antibodies in a cell-based bioassay. Of the 13 patients with available follow-up data, 5 patients remained positive for neutralizing antibodies at the end of the studies. No correlation between antibody development and adverse events was observed.
The detection of antibody formation is highly dependent on the sensitivity and specificity of the assays. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including sample handling, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Kineret with the incidence of antibodies to other products may be misleading.
Cholesterol elevations were observed in some patients treated with Kineret.
Other Adverse Events
Table 1 reflects adverse events in Studies 1 and 4, that occurred with a frequency of ≥ 5% in Kineret-treated patients over a 6-month period.
Table 1: Percent of RA Patients Reporting Adverse Events (Studies 1 and 4)
(n = 733)
|Kineret 100 mg/day|
(n = 1565)
|Injection Site Reaction||29%||71%|
|Worsening of RA||29%||19%|
|Upper Respiratory Tract Infections||17%||14%|
|Flu Like Symptoms||6%||6%|
Clinical Study Experience In NOMID
The data described herein reflect an open-label study in 43 NOMID patients exposed to Kineret for up to 60 months adding up to a total exposure of 159.8 patient years.
Patients were treated with a starting dose of 1 to 2 mg/kg/day and an average maintenance dose of 3-4 mg/kg/day adjusted depending on the severity of disease. Among pediatric NOMID patients, doses up to 7.6 mg/kg/day have been maintained for up to 15 months.
There were 24 serious adverse events (SAEs) reported in 14 of the 43 treated patients. The most common type of SAEs reported were infections. Five SAEs were related to lumbar puncture, which was part of the study procedure.
There were no permanent discontinuations of study drug treatment due to AEs. Doses were adjusted in 5 patients because of AEs; all were dose increases in connection with disease flares.
The reporting frequency of AEs was highest during the first 6 months of treatment. The incidence of AEs did not increase over time, and no new types of AEs emerged.
The most commonly reported AEs during the 60-month study period, calculated as the number of events/patient years of exposure, were arthralgia, headache, pyrexia, upper respiratory tract infection, nasopharyngitis, and rash.
The AE profiles for different age groups <2 years, 2-11 years, and 12-17 years corresponded to the AE profile for patients ≥18 years, with the exception of infections and related symptoms being more frequent in patients <2 years.
The reporting rate for infections was higher during the first 6 months of treatment (2.3 infections/patient-year) compared to after the first 6 months (1.7 infections/patient year). The most common infections were upper respiratory tract infection, sinusitis, ear infections, and nasopharyngitis.
There were no deaths or permanent treatment discontinuations due to infections. In one patient Kineret administration was temporarily stopped during an infection and in 5 patients the dose of Kineret was increased due to disease flares in connection with infections. Thirteen infections in 7 patients were classified as serious, the most common being pneumonia and gastroenteritis occurring in 3 and 2 patients, respectively. No serious opportunistic infections were reported.
The reporting frequency for infections was highest in patients <12 years of age.
After start of Kineret treatment neutropenia was reported in 2 patients. One of these patients experienced an upper respiratory tract infection and an otitis media infection. Both episodes of neutropenia resolved over time with continued Kineret treatment.
Injection Site Reactions
In total, 17 injection site reactions (ISRs) were reported in 10 patients during the 60-month study period. Out of the 17 ISRs, 11 (65%) occurred during the first month and 13 (76%) were reported during the first 6 months. No ISR was reported after Year 2 of treatment. The majority of ISRs were reported as mild (76% mild, 24% moderate). No patient permanently or temporarily discontinued Kineret treatment due to injection site reactions.
The immunogenicity of Kineret in NOMID patients was not evaluated.
Table 2: Most common (>10% of patients) treatment-emergent adverse events during the first 6 months of Kineret treatment
|Preferred term||Safety population|
(N=43) Total exposure in patient years= 20.8
|N (%)||Number of events /patient year|
|Injection site reaction||7 (16.3%)||0.5|
The most common adverse reactions occurring after the first 6-month period of treatment with Kineret (up to 60 months of treatment) included:
- upper respiratory tract infection,
- nasopharyngitis, and
The following adverse reactions have been identified during postapproval use of Kineret. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
- elevations of transaminases,
- non-infectious hepatitis
What drugs interact with Kineret (anakinra)?
No drug-drug interaction studies in human subjects have been conducted. Toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either methotrexate or Kineret when the two agents were administered together.
TNF Blocking Agents
A higher rate of serious infections has been observed in patients treated with concurrent Kineret and etanercept therapy than in patients treated with etanercept alone. Two percent of patients treated concurrently with Kineret and etanercept developed neutropenia (ANC < 1 x 109/L). Use of Kineret in combination with TNF blocking agents is not recommended.
Kineret (anakinra) is an injectable, interleukin-1 (IL-1) receptor antagonist that blocks the effects of human interleukin-1 used to treat the signs and symptoms of moderate to severe rheumatoid arthritis in individuals 18 years of age or older. Common side effects of Kineret include injection site reactions (redness, swelling and pain), headache, flu-like symptoms, diarrhea, and nausea. Kineret has not been studied in pregnant women. It is unknown if Kineret is excreted in the breast milk of females who are nursing. Consult your doctor before breastfeeding.
Multimedia: Slideshows, Images & Quizzes
What Is Rheumatoid Arthritis (RA)? Symptoms, Treatment, Diagnosis
What is rheumatoid arthritis (RA)? Learn about treatment, diagnosis, and the symptoms of juvenile rheumatoid arthritis. Discover...
Osteoarthritis (OA): Treatment, Symptoms, Diagnosis
Osteoarthritis (OA) is a degenerative joint disease most often affecting major joints such as knees, hands, back, or hips....
Exercises for Knee Osteoarthritis and Joint Pain
Learn about osteoarthritis and exercises that relieve knee osteoarthritis pain, stiffness and strengthen the knee joint and...
Osteoarthritis Quiz: Test Your Medical IQ
How does osteoarthritis differ from other types of arthritis? Learn about osteoarthritis with this quiz.
Rheumatoid Arthritis Exercises: Joint-Friendly Workouts
Regular exercise boosts fitness and helps reverse joint stiffness for people with rheumatoid arthritis (RA). WebMD demonstrates...
Rheumatoid Arthritis Quiz: What is Rheumatoid Arthritis?
How is rheumatoid arthritis different from other forms of arthritis, such as osteoarthritis and gout? Take the Rheumatoid...
Psoriatic Arthritis Quiz: Test Your Medical IQ
How is psoriatic arthritis related to psoriasis? Take this quiz to find out!
Picture of Psoriatic Arthritis
Psoriatic arthritis is a specific condition in which a person has both psoriasis and arthritis. See a picture of Psoriatic...
Picture of Osteoarthritis
Osteoarthritis is a type of arthritis that is caused by the breakdown and eventual loss of the cartilage of one or more...
Psoriatic Arthritis Symptoms, Treatment, Diagnosis
Psoriatic arthritis pain can be treated. Get more information on the causes, symptoms, diagnosis, and medications for psoriatic...
Osteoarthritis: 15 Tips to Improve Daily Living With OA
Have arthritis in the knee? Osteoarthritis joint pain can make it hard to carry out activities of daily living. Cartilage...
Tips for Healthy Joints: Exercise, Nutrition, & More
Dealing with joint pain and arthritis? Learn why weight matters--and why NOT to stretch before exercise. See these solutions for...
Arthritis: 16 Bad Habits That Cause Joint Pain
Being overweight, wearing uncomfortable shoes, or carrying a heavy purse can make joint pain and arthritis symptoms worse. Some...
Famous Faces With Rheumatoid Arthritis
Learn more about the famous faces of rheumatoid arthritis such as Lucille Ball, Glenn Frey, and more.
Arthritis: Causes and Treatment for Joint Stiffness and Pain
Arthritis and injuries can leave your joints swollen, tender, and damaged. Discover treatments for morning stiffness, sore...
Fun With Kids? Don't Let Arthritis Stop You
You can still have lots of fun with children despite arthritis. Our experts uncover ways to spend time with your kids or...
Active Living with Osteoarthritis
Check out this slideshow on Active Living From Day to Night with Osteoarthritis. Even with arthritis you can keep your active...
Related Disease Conditions
Buildup of uric acid crystals in a joint causes gouty arthritis. Symptoms and signs include joint pain, swelling, heat, and redness, typically of a single joint. Gout may be treated with diet and lifestyle changes, as well as medication.
Rheumatoid Arthritis (RA)
Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints, the tissue around the joints, as well as other organs in the body. Early RA signs and symptoms include anemia, both sides of the body affected (symmetric), depression, fatigue, fever, joint deformity, joint pain, joint redness, joint stiffness, joint swelling, joint tenderness, joint warmth, limping, loss of joint function, loss of joint range of motion, and polyarthritis.
Pain Management and Rheumatoid Arthritis
Second Source article from WebMD
Osteoarthritis is a type of arthritis caused by inflammation, breakdown, and eventual loss of cartilage in the joints. Also known as degenerative arthritis, osteoarthritis can be caused by aging, heredity, and injury from trauma or disease.
Arthritis (Joint Inflammation)
Arthritis is inflammation of one or more joints. When joints are inflamed they can develop stiffness, warmth, swelling, redness and pain. There are over 100 types of arthritis, including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, lupus, gout, and pseudogout.
16 Early Rheumatoid Arthritis (RA) Signs & Symptoms
Early rheumatoid arthritis (RA) symptoms and signs vary differently from person to person. The most common body parts that are initially affected by RA include the small joints of the hands, wrists, and feet, and the knees and hip joints. Joint inflammation causes stiffness. Warmth, redness, and pain may vary in degree.
Psoriatic arthritis is a disease that causes skin and joint inflammation. Symptoms and signs include painful, stiff, and swollen joints, tendinitis, and organ inflammation. Treatment involves anti-inflammatory medications and exercise.
Osteoarthritis vs. Osteoporosis Differences and Similarities
Arthritis is defined as painful inflammation and joint stiffness. Osteoarthritis is a type of arthritis and the most common cause of chronic joint pain, affecting over 25 million Americans. Osteoarthritis is a type of arthritis that involves the entire joint. Osteoporosis is not a type of arthritis. It is a disease that mainly is caused by a loss of bone tissue that is not limited to the joint areas. It is possible for one person to have both osteoarthritis and osteoporosis. The differences in the signs and symptoms of osteoarthritis and osteoporosis include; pain, stiffness, and joint swelling, joint deformity, crackle sounds when the joint is moving, and walking with a limp. Osteoporosis is called the "silent disease" because it can progress for years without signs and symptoms before it is diagnosed, severe back pain, bone fractures, height loss, and difficulty or inability to walk. The differences in the causes of osteoarthritis and osteoporosis are that osteoarthritis usually is caused by wear and tear on the joints. Osteoporosis usually is caused by one or more underlying problems, for example, calcium and vitamin D deficiencies. Treatment for osteoarthritis and osteoporosis are not the same. There is no cure for osteoarthritis or osteoporosis.
Fungal arthritis is inflammation of a joint by a fungus that has invaded the body and is growing in the normally sterile joint. Fungal arthritis symptoms and signs include pain, redness, loss of range of motion, and swelling. Fungal arthritis treatment includes antibiotics, adequate drainage of the joint, and sometimes surgery.
Septic arthritis, or infectious arthritis, is infection of one or more joints by bacteria, viruses, or fungi. Symptoms and signs of septic arthritis include fever, joint pain, chills, swelling, redness, warmth, and stiffness. Treatment involves antibiotics and the drainage of the infected joint.
Reactive arthritis is a chronic, systemic rheumatic disease characterized by three conditions, including conjunctivitis, joint inflammation, and genital, urinary, or gastrointestinal system inflammation. Inflammation leads to pain, swelling, warmth, redness, and stiffness of the affected joints. Non-joint areas may experience irritation and pain. Treatment for reactive arthritis depends on which area of the body is affected. Joint inflammation is treated with anti-inflammatory medications.
Rheumatoid Arthritis vs. Fibromyalgia
Though rheumatoid arthritis (RA) and fibromyalgia have similar symptoms, RA is an autoimmune disease and fibromyalgia is a chronic pain syndrome. RA symptoms include joint redness, swelling, and pain that lasts more than 6 weeks. Fibromyalgia symptoms include widespread pain, tingling feet or hands, depression, and bowel irritability. Home remedies for both include stress reduction, exercise, and getting enough sleep.
Rheumatoid Arthritis vs. Arthritis
Arthritis is a general term used to describe joint disease. Rheumatoid arthritis (RA) is a type of arthritis in which the body’s immune system mistakenly attacks the joints, causing chronic inflammation.
Juvenile Rheumatoid Arthritis (JRA)
Juvenile rheumatoid arthritis (JRA) annually affects one child in every thousand. There are six types of JRA. Treatment of juvenile arthritis depends upon the type the child has and should focus on treating the symptoms that manifest.
Osteoarthritis vs. Rheumatoid Arthritis
Osteoarthritis (OA) and rheumatoid arthritis (RA) are chronic joint disorders. RA is also an autoimmune disease. OA and RA symptoms and signs include joint pain, warmth, and tenderness. Over-the-counter pain relievers treat both diseases. There are several prescription medications that treat RA.
Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Non-radiographic spondyloarthritis (nr-axSpA) is an inflammatory arthritis that mainly affects the joints of the spine. Morning stiffness and back pain are the usual symptoms of nr-axSpA. Nonsteroidal anti-inflammatory drugs, exercise, and biologics are treatments for nr-axSpA.
Quackery of Arthritis
Arthritis patients are sometimes vulnerable to quackery (the business of promoting unproven remedies). These "quick fix" treatments are promoted as cure-alls, but they really have no right to such claims. Consumers should be wary of products that have marketing claims like "will cure," "ancient remedy," "has no side effects," and "revolutionary new scientific breakthrough." Read about arthritis remedies and tests that have no scientific proof of benefits.
Treatment & Diagnosis
- Rheumatoid Arthritis FAQs
- Psoriatic Arthritis FAQs
- Osteoarthritis FAQs
- Rheumatoid Arthritis (RA): 17 Warning Signs of Serious Complications
- Will Rheumatoid Arthritis Nodules Go Away?
- Is Inflammatory Arthritis the Same as Rheumatoid Arthritis?
- Living With Rheumatoid Arthritis
- What if I get COVID-19 with Rheumatoid Arthritis?
- Rheumatoid Arthritis vs. Osteoarthritis
- Patient Story: Rheumatoid Arthritis and Pregnancy
- Patient Story: Rheumatoid Arthritis Symptoms
- Rheumatoid Arthritis Joint Symptoms and Signs: What Do They Mean?
- Rheumatoid Arthritis: Which Patients Do Best?
- 5 Surprising Facts About Rheumatoid Arthritis
- Treatment Update on Rheumatoid Arthritis
- Psoriasis, Lupus, Rheumatoid Arthritis Share One Gene
- Rheumatoid Arthritis & Diabetes Gene (PTPN22)
- Arthritis Foot Care - It's In the Shoes
- Rheumatoid Arthritis: Questions for Your Doctor
- Kineret (anakinra) for Rheumatoid Arthritis
- Osteoarthritis - Vitamin D May Prevent Progression
- Arava Approved For Rheumatoid Arthritis
- Arthritis Roller Coaster
- Arthritis - Whether Weather Affects Arthritis
- Arthritis Medications
- Smoking: A New Risk - Rheumatoid Arthritis
- What Not to Eat When You Have Arthritis
- How Do Arthritis Symptoms Start?
- Ultrasound Imaging of Joints in Rheumatoid Arthritis (RA)
- What Is Cervical Osteoarthritis?
- Does Crohn's Disease Cause Arthritis?
- What Causes Arthritis and Baker's Cyst?
- What Kind of Doctor Treats Ankylosing Spodylitis & Reactive Arthritis?
- Can Fifth Disease Cause Arthritis Pain?
- What Is Meant by Seronegative Arthritis?
- What Causes Early Onset of Hip Osteoarthritis?
- What Is the Prognosis for Osteoarthritis?
- What Are the Side Effects of Remicade for Rheumatoid Arthritis?
- What Is a Triple Arthrodesis Surgical Procedure?
- Should You Avoid Drinking Soda with Rheumatoid Arthrits?
- What Kind of Joint Injections Treat Osteoarthritis?
- What Are the Side Effects of Glucosamine?
- Can You Get a Cartilage Transplant?
- Does Glucosamine Cream Work for Arthritis?
- Can Glucosamine Treat Arthritis?
- Are Women More Susceptible to Osteoarthritis?
- Can Milk Allergy Cause Rheumatoid Arthritis?
- Osteoarthritis of the Hands
- Are Hidradenitis and Rheumatoid Arthritis Related?
- What Are the Different Types of Psoriatic Arthritis?
- How Is Arthritis Diagnosed?
- What Is Sero Negative Arthritis?
- Osteoarthritis vs. Carpal Tunnel: What's the Difference?
- Can My Diet Improve Arthritis?
- What's the Rheumatoid Arthritis Prognosis?
- What Are Home Remedies for Rheumatoid Arthritis?
- Patient Story: Rheumatoid Arthritis Treatment
- Rheumatoid Arthritis: Living With a Chronic Disease
- Osteoarthritis Symptoms
Medications & Supplements
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Professional side effects and drug interactions sections courtesy of the U.S. Food and Drug Administration.
3. National Cancer Institute. Surveillance, Epidemiology, and End Results Database (SEER) Program. SEER Incidence Crude Rates, 11 Registries, 1992-1999.